Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURULICO: Antibiotic Treatment for Early Buruli Ulcer
NCT00321178Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- May 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clarithromycin in Buruli ulcer (BU) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Healing without recurrence and without debridement surgery at 12 months. Started May 2006; status: completed.
02
Drugs
clarithromycin
03
Conditions
Buruli ulcer (BU)
Beyond the preview
Go deeper on NCT00321178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321178.